Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / AGNPF - Algernon gets notice of allowance for patent to treat chronic kidney disease in Japan

AGNPF - Algernon gets notice of allowance for patent to treat chronic kidney disease in Japan

Algernon Pharmaceuticals Inc - Class A

--News Direct--

Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company has been granted a patent in Japan for its work around the Compositions and Methods for Treating Chronic Kidney Disease with drug NP-251 or Repirinast.

Moreau telling Proactive this now repurposed drug was approved in the Japanese market for the treatment of asthma and this is now quite significant for its approval for use in the treatment of renal fibrosis or kidney disease.

Repirinast has data showing it reduced fibrosis by 51% with statistical significance and showed an additive benefit to medicine blood pressure drug telmisartan in a unilateral ureteral obstruction mouse model.

Contact Details

Proactive Canada

+1 604-688-8158

na-editorial@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/algernon-gets-notice-of-allowance-for-patent-to-treat-chronic-kidney-disease-in-japan-267469556

Stock Information
Company Name: Algernon Pharmaceuticals Inc - Class A
Stock Symbol: AGNPF
Market: OTC
Website: algernonpharmaceuticals.com
Menu
AGNPF AGNPF Quote AGNPF Short AGNPF News AGNPF Articles AGNPF Message Board
Get AGNPF Alerts

News, Short Squeeze, Breakout and More Instantly...